331 related articles for article (PubMed ID: 27483130)
1. Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder.
Sayer GR; McGough JJ; Levitt J; Cowen J; Sturm A; Castelo E; McCracken JT
J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):882-888. PubMed ID: 27483130
[TBL] [Abstract][Full Text] [Related]
2. Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study.
McCracken JT; McGough JJ; Loo SK; Levitt J; Del'Homme M; Cowen J; Sturm A; Whelan F; Hellemann G; Sugar C; Bilder RM
J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):657-666.e1. PubMed ID: 27453079
[TBL] [Abstract][Full Text] [Related]
3. Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder.
Bilder RM; Loo SK; McGough JJ; Whelan F; Hellemann G; Sugar C; Del'Homme M; Sturm A; Cowen J; Hanada G; McCracken JT
J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):667-73. PubMed ID: 27453080
[TBL] [Abstract][Full Text] [Related]
4. Effects of d-Methylphenidate, Guanfacine, and Their Combination on Electroencephalogram Resting State Spectral Power in Attention-Deficit/Hyperactivity Disorder.
Loo SK; Bilder RM; Cho AL; Sturm A; Cowen J; Walshaw P; Levitt J; Del'Homme M; Piacentini J; McGough JJ; McCracken JT
J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):674-682.e1. PubMed ID: 27453081
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
[TBL] [Abstract][Full Text] [Related]
7. Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy.
Schneider G; Banaschewski T; Feldman BL; Gustafsson PA; Murphy B; Reynolds M; Coghill DR; Spalding WM
J Child Adolesc Psychopharmacol; 2019 May; 29(4):285-304. PubMed ID: 30942617
[No Abstract] [Full Text] [Related]
8. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
Childress A; Hoo-Cardiel A; Lang P
Expert Opin Pharmacother; 2020 Mar; 21(4):417-426. PubMed ID: 31971448
[No Abstract] [Full Text] [Related]
10. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
Kisicki JC; Fiske K; Lyne A
Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
[TBL] [Abstract][Full Text] [Related]
11. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
Kollins SH; López FA; Vince BD; Turnbow JM; Farrand K; Lyne A; Wigal SB; Roth T
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
Newcorn JH; Stein MA; Childress AC; Youcha S; White C; Enright G; Rubin J
J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
[TBL] [Abstract][Full Text] [Related]
13. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
[TBL] [Abstract][Full Text] [Related]
14. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Childress AC
Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of guanfacine extended release in adolescents aged 13-17 years with attention-deficit/hyperactivity disorder.
Martin P; Satin L; Vince BD; Padilla AF; White C; Corcoran M; Stevenson A; Ermer J
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):252-61. PubMed ID: 27128830
[TBL] [Abstract][Full Text] [Related]
16. ▼Guanfacine for ADHD in children and adolescents.
Drug Ther Bull; 2016 May; 54(5):56-60. PubMed ID: 27173784
[TBL] [Abstract][Full Text] [Related]
17. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
Martinez-Raga J; Knecht C; Szerman N; Martinez MI
CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
[TBL] [Abstract][Full Text] [Related]
18. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.
Connor DF; Findling RL; Kollins SH; Sallee F; López FA; Lyne A; Tremblay G
CNS Drugs; 2010 Sep; 24(9):755-68. PubMed ID: 20806988
[TBL] [Abstract][Full Text] [Related]
19. Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study.
Butterfield ME; Saal J; Young B; Young JL
Psychiatry Res; 2016 Feb; 236():136-141. PubMed ID: 26730446
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Spencer TJ; Greenbaum M; Ginsberg LD; Murphy WR
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):501-10. PubMed ID: 19877974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
